KR20240082380A - 골형성 부전증의 치료에 항-스클레로스틴 항체를 사용하는 방법 - Google Patents

골형성 부전증의 치료에 항-스클레로스틴 항체를 사용하는 방법 Download PDF

Info

Publication number
KR20240082380A
KR20240082380A KR1020247013976A KR20247013976A KR20240082380A KR 20240082380 A KR20240082380 A KR 20240082380A KR 1020247013976 A KR1020247013976 A KR 1020247013976A KR 20247013976 A KR20247013976 A KR 20247013976A KR 20240082380 A KR20240082380 A KR 20240082380A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
sclerostin antibody
sclerostin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247013976A
Other languages
English (en)
Korean (ko)
Inventor
알라스테어 맥키넌
아룬 미스트리
에밀 카키스
마이클 에스. 오민스키
Original Assignee
메레오 바이오파마 3 리미티드
울트라제닉스 파마수티컬 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메레오 바이오파마 3 리미티드, 울트라제닉스 파마수티컬 인코포레이티드 filed Critical 메레오 바이오파마 3 리미티드
Publication of KR20240082380A publication Critical patent/KR20240082380A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020247013976A 2021-09-30 2022-09-29 골형성 부전증의 치료에 항-스클레로스틴 항체를 사용하는 방법 Pending KR20240082380A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163250918P 2021-09-30 2021-09-30
US63/250,918 2021-09-30
US202263374982P 2022-09-08 2022-09-08
US63/374,982 2022-09-08
PCT/US2022/077259 WO2023056355A2 (en) 2021-09-30 2022-09-29 Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta

Publications (1)

Publication Number Publication Date
KR20240082380A true KR20240082380A (ko) 2024-06-10

Family

ID=85783647

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247013976A Pending KR20240082380A (ko) 2021-09-30 2022-09-29 골형성 부전증의 치료에 항-스클레로스틴 항체를 사용하는 방법

Country Status (9)

Country Link
US (1) US20250011407A1 (https=)
EP (1) EP4408884A4 (https=)
JP (1) JP2024536106A (https=)
KR (1) KR20240082380A (https=)
AU (1) AU2022357544A1 (https=)
CA (1) CA3233220A1 (https=)
MX (1) MX2024003828A (https=)
TW (1) TW202323278A (https=)
WO (1) WO2023056355A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025212547A1 (en) * 2024-04-05 2025-10-09 Amgen Inc. Methods of treating osteogenesis imperfecta

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011517672A (ja) * 2008-03-24 2011-06-16 アボツト・バイオテクノロジー・リミテツド 骨損失を治療するための方法及び組成物
MA41142A (fr) * 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
KR20190037261A (ko) * 2016-08-08 2019-04-05 암젠 인크 항-스클레로스틴 항체를 사용한 결합 조직 부착 개선 방법
MX2019007161A (es) * 2016-12-21 2020-02-12 Mereo Biopharma 3 Ltd Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
US10961305B2 (en) * 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
GB201810746D0 (en) * 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist

Also Published As

Publication number Publication date
JP2024536106A (ja) 2024-10-04
EP4408884A2 (en) 2024-08-07
TW202323278A (zh) 2023-06-16
AU2022357544A1 (en) 2024-04-11
CA3233220A1 (en) 2023-04-06
MX2024003828A (es) 2024-05-10
US20250011407A1 (en) 2025-01-09
WO2023056355A2 (en) 2023-04-06
EP4408884A4 (en) 2025-04-23
WO2023056355A3 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
US12582712B2 (en) Method of making anti-pro/latent myostatin antibodies
US11925683B2 (en) Compositions for making and using anti-Myostatin antibodies
US7744874B2 (en) Anti-sclerostin antibodies
TWI636993B (zh) Ｄｋｋ１抗體及使用方法
US20250011407A1 (en) Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta
CN117730095A (zh) 中度至重度成骨不全症的治疗

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000